The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease-Reference-Cited by-同舟云学术

The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease

Published:2018-10-24 Issue:3 Volume:49 Page:339-363
ISSN:0953-816X
Container-title:European Journal of Neuroscience
language:en
Short-container-title:Eur J Neurosci

Author:

Cresto Noémie¹,Gardier Camille¹,Gubinelli Francesco¹,Gaillard Marie-Claude¹,Liot Géraldine¹,West Andrew B.²,Brouillet Emmanuel¹^ORCID

Affiliation:

1. Neurodegenerative Diseases Laboratory, UMR9199, CEA, CNRS; Université Paris Sud, Université Paris-Saclay, and MIRCen (Molecular Imaging Research Centre), Institut François Jacob, DRF, CEA; Fontenay-aux-Roses France

2. Center for Neurodegeneration and Experimental Therapeutics; University of Alabama at Birmingham; Birmingham Alabama

Funder

European Union Horizon 2020 Programme

Marie Skłodowska-Curie Innovative Training Network

“Fondation de France, Parkinson committee”

NeurATRIS, “Investissement d'Avenir”

National Institutes of Health

Publisher

Wiley

Subject

General Neuroscience

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejn.14182/fullpdf

Reference259 articles.

1. α-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic neurodegeneration;Abdelmotilib;Neurobiology of Diseases,2017

2. PET in LRRK2 mutations: Comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation;Adams;Brain,2005

3. An intralysosomal hsp70 is required for a selective pathway of lysosomal protein degradation;Agarraberes;Journal of Cell Biology,1997

4. Development and characterization of a new Parkinson's disease model resulting from impaired autophagy;Ahmed;Journal of Neuroscience,2012

5. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model;Alegre-Abarrategui;Human Molecular Genetics,2009

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beta2-Adrenergic Suppression of Neuroinflammation in Treatment of Parkinsonism, with Relevance for Neurodegenerative and Neoplastic Disorders;Biomedicines;2024-08-01

2. Emerging perspectives on precision therapy for Parkinson’s disease: multidimensional evidence leading to a new breakthrough in personalized medicine;Frontiers in Aging Neuroscience;2024-07-04

3. Misfolded alpha‐synuclein in amyotrophic lateral sclerosis: Implications for diagnosis and treatment;European Journal of Neurology;2024-01-25

4. Beta₂-Adrenergic Agonists in Treatment for Parkinsonism, with Implications for Neurodegenerative and Neoplastic Disorders;2024-01-17

5. Total Glucosides of White Paeony Capsule ameliorates Parkinson's disease-like behavior in MPTP-induced mice model by regulating LRRK2/alpha-synuclein signaling;Journal of Ethnopharmacology;2024-01